Valuation: Theralase Technologies Inc.

Market Cap 75.4M 53.7M 46.94M 43.41M 39.84M 5.17B 76.71M 518M 203M 2.53B 202M 197M 8.72B P/E 2026 *
-25.5x
P/E 2027 * 12.8x
Enterprise Value 75.4M 53.7M 46.94M 43.41M 39.84M 5.17B 76.71M 518M 203M 2.53B 202M 197M 8.72B EV / Sales 2026 *
94x
EV / Sales 2027 * 2.22x
Free-Float
87.46%
Yield 2026 *
-
Yield 2027 * -
1 week-7.27%
1 month+6.25%
3 months-16.39%
6 months-5.56%
Current year+54.55%
1 week 0.26
Extreme 0.255
0.28
1 month 0.22
Extreme 0.225
0.28
Current year 0.16
Extreme 0.16
0.41
1 year 0.14
Extreme 0.145
0.41
3 years 0.14
Extreme 0.14
0.41
5 years 0.14
Extreme 0.14
0.48
10 years 0.12
Extreme 0.12
0.6
Manager TitleAgeSince
Chief Executive Officer - 29/06/2023
Director of Finance/CFO - 27/06/2019
Chief Executive Officer - 15/11/2021
Director TitleAgeSince
Chairman - -
Director/Board Member - 01/01/2008
Director/Board Member - 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
21/05/26 Buy

Director

20,900 0.0081%
20/05/26 Sell

Director

11,000 0.0043%
20/05/26 Sell

Director

20,900 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.27%+24.39%-13.56% 53.67M
+0.55%+2.28%+44.55%+50.05% 1.51B
-3.25%-5.93%-46.88%-55.01% 276M
-2.22%+3.29%-9.09%-51.65% 54.67M
Average -1.23%-0.14%+3.24%-17.54% 473.88M
Weighted average by Cap. -0.10%+1.04%+29.14%+30.04%

Financials

2026 *2027 *
Net sales 802K 571K 499K 462K 424K 55.05M 816K 5.51M 2.16M 26.88M 2.15M 2.1M 92.8M 33.89M 24.14M 21.1M 19.51M 17.91M 2.33B 34.48M 233M 91.41M 1.14B 90.65M 88.66M 3.92B
Net income -4.2M -2.99M -2.61M -2.42M -2.22M -288M -4.27M -28.84M -11.33M -141M -11.23M -10.99M -486M 6.83M 4.87M 4.25M 3.93M 3.61M 469M 6.95M 46.91M 18.43M 229M 18.27M 17.87M 790M
Net Debt - -
Logo Theralase Technologies Inc.
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Employees
20
Date Price Change Volume
16/07/26 CA$0.2550 0.00% 65,964
15/07/26 CA$0.2550 -3.77% 18,002
14/07/26 CA$0.2650 +1.92% 5,152
13/07/26 CA$0.2600 0.00% 132,190
10/07/26 CA$0.2600 -5.45% 140,775
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2550CAD
Average target price
0.7000CAD
Spread / Average Target
+174.51%

Quarterly revenue - Rate of surprise